Last reviewed · How we verify

XR-tacrolimus QD + MMF BID

University Hospital, Limoges · FDA-approved active Small molecule

XR-tacrolimus and MMF work together as immunosuppressants to prevent organ rejection by inhibiting T-cell activation and proliferation.

XR-tacrolimus and MMF work together as immunosuppressants to prevent organ rejection by inhibiting T-cell activation and proliferation. Used for Prevention of organ rejection in transplant recipients (renal, cardiac, hepatic transplantation).

At a glance

Generic nameXR-tacrolimus QD + MMF BID
SponsorUniversity Hospital, Limoges
Drug classCalcineurin inhibitor + Antimetabolite immunosuppressant combination
TargetCalcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)
ModalitySmall molecule
Therapeutic areaImmunology / Transplantation
PhaseFDA-approved

Mechanism of action

Tacrolimus is a calcineurin inhibitor that blocks T-cell receptor signaling by inhibiting calcineurin phosphatase, preventing IL-2 production and T-cell activation. Mycophenolate mofetil (MMF) is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH) that depletes guanosine nucleotides in T and B lymphocytes, further suppressing immune proliferation. Together, they provide synergistic immunosuppression for transplant rejection prevention.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: